Paul Choi is ranked #2478 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Paul Choi (Goldman Sachs) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Paul Choi's stock ratings?

About 31% of Paul's ratings were profitable over a one-year hold, with an average return of -7.2% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Paul Choi

Paul Choi

Goldman Sachs

Wall Street Analyst

★☆☆☆☆

#2478

on 13Foresight · ranked by our own returns

31%

Success Rate

-7.1%

Average Return

12 of 39 calls profitable · -17.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 31% of Paul Choi's ratings turned a profit when each position was held for 1 year — averaging -7.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 15 Hold 8 Sell

Paul's Stock Coverage 36 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
EWTX Edgewise Therapeutics	Jun 17, 2026	HOLD	Strong Buy +22.4% avg upside 14 analysts	$32.00 13.14% Downside	·
VERA Vera Therapeutics	Jun 05, 2026	BUY	Strong Buy +91.0% avg upside 19 analysts	$90.00 156.58% Upside	+0.0%
URGN Urogen Pharma	May 18, 2026	HOLD	Strong Buy +13.0% avg upside 16 analysts	$18.00 46.30% Downside	+14.8%
CRVS Corvus Pharmaceuticals	May 14, 2026	BUY	Strong Buy +114.5% avg upside 14 analysts	$40.00 235.80% Upside	-12.1%
RGNX RegenXBio	May 14, 2026	HOLD	Strong Buy +381.4% avg upside 22 analysts	$10.00 28.21% Upside	-8.3%
ARVN Arvinas Holding Company	May 12, 2026	SELL	Buy +264.5% avg upside 27 analysts	$6.00 21.86% Downside	+20.8%
BBIO BridgeBio Pharma	May 08, 2026	BUY	Strong Buy +38.7% avg upside 34 analysts	$116.00 75.05% Upside	+0.0%
LNTH Lantheus	May 07, 2026	HOLD	Strong Buy -27.9% avg upside 20 analysts	$94.00 9.47% Downside	+15.0%
EXEL Exelixis	May 06, 2026	BUY	Strong Buy -21.0% avg upside 33 analysts	$50.00 3.73% Downside	+9.1%
VIR Vir Biotechnology	May 06, 2026	BUY	Strong Buy +185.4% avg upside 16 analysts	$21.00 129.18% Upside	-9.6%
CYTK Cytokinetics	May 05, 2026	BUY	Strong Buy +8.9% avg upside 36 analysts	$101.00 28.24% Upside	+2.5%
PHAT Phathom Pharmaceuticals	Apr 30, 2026	HOLD	Strong Buy +163.8% avg upside 14 analysts	—	-2.9%
ASND Ascendis Pharma	Apr 08, 2026	BUY	Strong Buy +17.0% avg upside 24 analysts	$255.00 10.51% Upside	-0.9%
XENE Xenon	Mar 10, 2026	BUY	Strong Buy +19.0% avg upside 28 analysts	$75.00 41.67% Upside	-13.6%
ESPR Esperion	Mar 03, 2026	HOLD	Buy +701.2% avg upside 22 analysts	$3.00 4.69% Downside	+8.2%
AMRN Amarin	Feb 25, 2026	SELL	Buy -47.3% avg upside 18 analysts	$12.00 25.18% Downside	-12.2%
GOSS Gossamer Bio	Feb 24, 2026	HOLD	Buy +4379.4% avg upside 17 analysts	$0.50 197.53% Upside	-17.1%
PTCT PTC Therapeutics	Dec 03, 2025	SELL	Buy -1.5% avg upside 29 analysts	$55.00 30.28% Downside	-3.7%
KNSA Kiniksa Pharmaceuticals	Oct 29, 2025	BUY	Strong Buy -0.2% avg upside 11 analysts	$55.00 0.17% Downside	+40.0%
LINK Interlink Electronics	Feb 11, 2025	HOLD	Strong Buy +117.4% avg upside 16 analysts	—	-25.2%
PMVP PMV Pharmaceuticals	Dec 19, 2024	HOLD	Strong Buy +1200.9% avg upside 12 analysts	—	-17.3%
KYNB Kyntra Bio	Dec 19, 2024	HOLD	Buy +370.8% avg upside 14 analysts	—	-2.8%
HCM HUTCHMED	Jul 31, 2024	HOLD	Strong Buy +208.7% avg upside 9 analysts	$19.00 84.82% Upside	-8.5%
BMRN BioMarin Pharmaceutical	Jun 04, 2024	BUY	Strong Buy +72.8% avg upside 52 analysts	—	-29.1%
HK:0013 HUTCHMED (China)	Nov 10, 2023	HOLD	Buy +619.1% avg upside 6 analysts	$133.20 711.25% Upside	·
FHTX Foghorn Therapeutics	Jun 28, 2023	BUY	Strong Buy +187.5% avg upside 17 analysts	$19.00 357.90% Upside	-33.1%
SPRY ARS Pharmaceuticals	Apr 03, 2022	HOLD	Strong Buy +122.5% avg upside 12 analysts	$3.50 63.74% Downside	+95.4%
PBYI Puma Biotechnology	Nov 05, 2021	HOLD	Buy +458.2% avg upside 11 analysts	$7.00 7.51% Downside	-32.4%
KRRO Korro Bio	Sep 22, 2021	HOLD	Strong Buy +108.3% avg upside 19 analysts	$9.00 30.68% Downside	-75.3%
DNTH Dianthus Therapeutics	Mar 04, 2021	BUY	Strong Buy +8.8% avg upside 29 analysts	$17.00 79.49% Downside	-80.5%
ARRY Array Technologies	Nov 09, 2020	BUY	Buy +92.0% avg upside 37 analysts	$50.00 524.92% Upside	-48.6%
ODTC Odonate	Aug 24, 2020	SELL	Hold -99.9% avg upside 3 analysts	—	·
NBIX Neurocrine	Jun 29, 2020	HOLD	Strong Buy +7.8% avg upside 37 analysts	$135.00 14.80% Downside	-22.8%
NKTR Nektar Therapeutics	Mar 30, 2020	HOLD	Buy +16.5% avg upside 25 analysts	$20.00 67.28% Downside	+8.0%
INCY Incyte	Nov 01, 2017	BUY	Buy +1.0% avg upside 47 analysts	$165.00 67.97% Upside	-36.6%
LLY Eli Lilly & Co	Apr 07, 2017	BUY	Strong Buy -10.5% avg upside 47 analysts	$90.00 91.90% Downside	-7.5%

🔒 31 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Paul Choi — Frequently Asked Questions

How accurate are Paul Choi's stock ratings?

Based on the calls 13Foresight could measure, about 31% of Paul's ratings were profitable over a one-year hold, with an average return of -7.2% per rating, or -17.6% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Paul ranked on 13Foresight?

Paul Choi is currently ranked #2478 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Paul cover?

Paul most recently has ratings on EWTX, VERA, URGN, CRVS, RGNX, ARVN, BBIO, LNTH, EXEL, VIR, CYTK, PHAT and 24 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!